ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BNTC Benitec Biopharma Limited

8.8686
0.9686 (12.26%)
After Hours
Last Updated: 21:26:57
Delayed by 15 minutes
Share Name Share Symbol Market Type
Benitec Biopharma Limited NASDAQ:BNTC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.9686 12.26% 8.8686 8.50 9.50 9.46 8.1547 8.24 60,592 21:26:57

Report of Foreign Issuer (6-k)

01/08/2018 11:15am

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

 

For the month of July

 

Commission File Number 001-37518

 

Benitec Biopharma Limited
(Translation of registrant’s name into English)

 

Suite 1201, 99 Mount Street, North Sydney NSW 2060 AUSTRALIA

 (Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x     Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨     No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a

  

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Benitec Biopharma Limited
     
     
Date: 7/31/2018 By:

/s/ Oliver Kidd

  Name:   Oliver Kidd
  Title: Company Secretary

 

 

 

 

EXHIBIT INDEX

Exhibit

Number

 

Description

99.1  

Appendix 4C - quarterly

 

 

 

1 Year Benitec Biopharma Chart

1 Year Benitec Biopharma Chart

1 Month Benitec Biopharma Chart

1 Month Benitec Biopharma Chart

Your Recent History

Delayed Upgrade Clock